关键字: 类型:
下载页码(大于0,小于852):
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
 临床试验药物安全性 1506条(本栏目收费,不能显示细节,电话15274084725)
degree of certainty,229 229
primary objective of the study,228 228
treatment effect expected,229 229
statistical methods for determining trial size,231 231
statistical terms commonly used in sample size calculations,230 230
superiority analysis versus non-inferiority analysis,223,226 226
time to event variables,239,241 241
two-tailed test,212,214 214
writing a sample size section of a clinical study protocol,244,245 245
omalizumab for,80 80
Astrocytoma everolimus for,165 165
treating,267 267
Atherosclerosis C-reactive protein as biomarker,398,400 400
Atomexetine,698 698
package insert of,698,699 699
Adalimumab,538 538
Add-on design active control,59,60 60
Adefovir,166 166
Adjuvant therapy chronic drug administration,327 327
metastasis risk reduction,326,327 327
staging accuracy,327 327
meanings of adjuvant,327,328 328
Adverse drug reaction (ADR),70,71,79,104,105,108,136,162 162
Adverse event (AE) abnormal laboratory values,493 494 493 494
adverse drug reaction,494 494
anticipation in clinical study design,487 487
cause-and-effect data from raw data,522,523 523
anticipated versus unanticipated,500,502 502
drug induction,495,496 496
statistician considerations,496 496
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2019-0007 浙公网安备:33068302000535
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3